Biomea Fusion, Inc.
$1.30
-6.5%Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.1).
Valuation inputs: P/E -1.1, earnings yield N/A, momentum -6.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.1%, ROIC -1.7%).
Profitability stack: net margin 0.0%, ROE -2.1%, ROIC -1.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +49.5%, momentum -6.5%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Biomea Fusion, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Biomea Fusion, Inc. Fair Value Envelope
No Revenue Data
BMEA has not reported any revenue values in the available annual periods.
Biomea Fusion, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
BMEA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
BMEA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
BMEA has not reported any net profit margin values in the available annual periods.
Biomea Fusion, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Biomea Fusion, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Biomea Fusion, Inc. Street Expectations Map
Wall Street analysts project that BMEA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 20.20, with estimates ranging from a low of 10.00 to a high of 40.00.
The consensus 1-year price target stands at 20.20, with estimates ranging from a low of 10.00 to a high of 40.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Biomea Fusion, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.43M worth of BMEA shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
30.0K
43.00K
0
0.00
+43K
+$43K
6-9 Months
150.0K
153.73K
0
0.00
+154K
+$154K
9-12 Months
2.5M
4.23M
0
0.00
+4.2M
+$4.23M
Top Buyers
Erdtmann Rainer M
Director, Officer: See Remarks
$2.01M
Hitchcock Michael J.M.
Director, Officer: Interim Ceo
$1.50M
Ray Sumita
Director
$230K
Chen Bihua
Director, 10 Percent Owner:
$230K
Aguiar Eric
Director
$230K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.43M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
BMEA has not reported any dividend yield values in the available annual periods.
bmea Dividend History
Learning Layer
Related Guides
Build conviction on BMEA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.